Vaccine against streptococcus pneumoniae capsular polysaccharides
AssigneeSmithKline Beecham Biologicals s.a.
InventorsCarine Capiau, Marguerite Deschamps, Pierre Michel Desmons, Craig Antonyjoseph Laferriere, Jan Poolman, Jean-Paul Prieels
Life of this patent
Estimating the term…
Abstract
The present invention relates to the field of bacterial polysaccharide antigen vaccines. In particular, the present invention relates to specific advantageous pnumococcal polysaccharide conjugates adjuvanted with 3D-MPL and substantially devoid aluminium-based adjuvant.
Claims19
An antigenic composition comprising one or more Streptococcus pneumoniae capsular polysaccharide conjugates adjuvanted with 3D-MPL and substantially devoid of aluminium-based adjuvants, wherein at least one of the Streptococcus pneumoniae polysaccharide conjugates is significantly more immunogenic in compositions comprising 3D-MPL in comparison with compositions comprising 3D-MPL in conjunction with an aluminium-based adjuvant.
An antigenic composition substantially devoid of aluminium-based adjuvants and comprising 3D-MPL adjuvant and two or more pneumococcal polysaccharide conjugates chosen from the group consisting of:
- serotype 4;
- serotype 6B;
- serotype 18C;
- serotype 19F;
- and
- serotype 23F.
A method of inducing an immune response to a Streptococcus pneumoniae capsular polysaccharide conjugate, said method comprising administering a safe and effective amount of an antigenic composition as claimed herein to a patient.
Use of an antigenic composition as claimed herein in the manufacture of a medicament for the prevention of pneumococcal disease.
Dependencies are inferred from the claim text.